1887

Abstract

In a previous vaccination trial, inoculation of gene DNA failed to elicit a detectable antibody response, yet accelerated virus dissemination in most immunized cats following challenge with feline immunodeficiency virus. This result raised the possibility that cell-mediated immune responses had given rise to immune-mediated enhancement of infection. Since high-level replication of immunodeficiency viruses in lymphocytes requires cellular activation, antigen-specific responses or non-specific polyclonal activation may have increased the frequency of optimal target cells. In the present DNA vaccination trial, although designed so as to minimize non-specific polyclonal activation, immune-mediated enhancement was nonetheless observed in certain immunized cats. Moreover, rapid virus dissemination was associated with the presence of T-helper responses prior to challenge, and was linked to increased susceptibility of lymphocytes to infection. Immune activation may thus be a confounding factor in vaccination against lentivirus infection, diminishing vaccine efficacy and giving rise to immune-mediated enhancement.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-10-2515
2002-10-01
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/10/0832515a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-10-2515&mimeType=html&fmt=ahah

References

  1. Aida, Y. & Pabst, M. J. ( 1990; ). Removal of endotoxin from protein solutions by phase separation using Triton X-114. Journal of Immunological Methods 132, 191-195.[CrossRef]
    [Google Scholar]
  2. Ascher, M. S. & Sheppard, H. W. ( 1990; ). AIDS as immune system activation. II. The panergic imnesia hypothesis. Journal of Acquired Immune Deficiency Syndromes 3, 177-191.
    [Google Scholar]
  3. Bentwich, Z., Maartens, G., Torten, D., Lal, A. A. & Lal, R. B. ( 2000; ). Concurrent infections and HIV pathogenesis. AIDS 14, 2071-2081.[CrossRef]
    [Google Scholar]
  4. Brichacek, B., Swindells, S., Janoff, E. N., Pirruccello, S. & Stevenson, M. ( 1996; ). Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. Journal of Infectious Diseases 174, 1191-1199.[CrossRef]
    [Google Scholar]
  5. Bukrinsky, M. I., Stanwick, T. L., Dempsey, M. P. & Stevenson, M. ( 1991; ). Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254, 423-427.[CrossRef]
    [Google Scholar]
  6. Bush, C. E., Donovan, R. M., Markowitz, N. P., Kvale, P. & Saravolatz, L. D. ( 1996; ). A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 13, 23-26.[CrossRef]
    [Google Scholar]
  7. Davey, R. T.Jr, Chaitt, D. G., Piscitelli, S. C., Wells, M., Kovacs, J. A., Walker, R. E., Falloon, J., Polis, M. A., Metcalf, J. A., Masur, H., Fyfe, G. & Lane, H. C. ( 1997; ). Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. Journal of Infectious Diseases 175, 781-789.[CrossRef]
    [Google Scholar]
  8. Davis, H. L., Michel, M. L. & Whalen, R. G. ( 1993; ). DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human Molecular Genetics 2, 1847-1851.[CrossRef]
    [Google Scholar]
  9. Dawson, J. D. ( 1994; ). Comparing treatment groups on the basis of slopes, areas-under-the-curve, and other summary measures. Drug Information Journal 28, 723-732.
    [Google Scholar]
  10. Eaton, A. M., Ugen, K. E., Weiner, D. B., Wildes, T. & Levy, J. A. ( 1994; ). An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Research and Human Retroviruses 10, 13-18.[CrossRef]
    [Google Scholar]
  11. Fust, G., Toth, F. D., Kiss, J., Ujhelyi, E., Nagy, I. & Banhegyi, D. ( 1994; ). Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS 8, 603-609.[CrossRef]
    [Google Scholar]
  12. Goletti, D., Weissman, D., Jackson, R. W., Graham, N. M., Vlahov, D., Klein, R. S., Munsiff, S. S., Ortona, L., Cauda, R. & Fauci, A. S. ( 1996; ). Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. Journal of Immunology 157, 1271-1278.
    [Google Scholar]
  13. Hesselink, W., Sondermeijer, P., Pouwels, H., Verblakt, E. & Dhore, C. ( 1999; ). Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge. Veterinary Microbiology 69, 109-110.[CrossRef]
    [Google Scholar]
  14. Homsy, J., Meyer, M., Tateno, M., Clarkson, S. & Levy, J. A. ( 1989; ). The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244, 1357-1360.[CrossRef]
    [Google Scholar]
  15. Homsy, J., Meyer, M. & Levy, J. A. ( 1990; ). Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. Journal of Virology 64, 1437-1440.
    [Google Scholar]
  16. Hosie, M. J., Osborne, R., Reid, G., Neil, J. C. & Jarrett, O. ( 1992; ). Enhancement after feline immunodeficiency virus vaccination. Veterinary Immunology and Immunopathology 35, 191-197.[CrossRef]
    [Google Scholar]
  17. Huisman, W., Karlas, J. A., Siebelink, K. H., Huisman, R. C., de Ronde, A., Francis, M. J., Rimmelzwaan, G. F. & Osterhaus, A. D. ( 1998; ). Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection. Vaccine 16, 181-187.[CrossRef]
    [Google Scholar]
  18. Johnston, M. I. ( 2000; ). The role of nonhuman primate models in AIDS vaccine development. Molecular Medicine Today 6, 267-270.[CrossRef]
    [Google Scholar]
  19. Jouault, T., Chapuis, F., Olivier, R., Parravicini, C., Bahraoui, E. & Gluckman, J.-C. ( 1989; ). HIV infection of monocytic cells: role of antibody-mediated virus binding to Fc-gamma receptors. AIDS 3, 125-133.[CrossRef]
    [Google Scholar]
  20. Karlas, J. A., Siebelink, K. H., van Peer, M. A., Huisman, W., Rimmelzwaan, G. F. & Osterhaus, A. D. ( 1998; ). Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells. Veterinary Immunology and Immunopathology 65, 353-365.[CrossRef]
    [Google Scholar]
  21. Karlas, J. A., Siebelink, K. H. J., van Peer, M. A., Huisman, W., Cuisinier, A. M., Rimmelzwaan, G. F. & Osterhaus, A. D. M. E. ( 1999; ). Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. Journal of General Virology 80, 761-765.
    [Google Scholar]
  22. Kostrikis, L. G., Cao, Y., Ngai, H., Moore, J. P. & Ho, D. D. ( 1996; ). Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of Virology 70, 445-458.
    [Google Scholar]
  23. Kovacs, J. A., Baseler, M., Dewar, R. J., Vogel, S., Davey, R. T., Jr, Falloon, J., Polis, M. A., Walker, R. E., Stevens, R., Salzman, N. P. and others ( 1995; ). Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. New England Journal of Medicine 332, 567–575.[CrossRef]
    [Google Scholar]
  24. Lallemant, M., Baillou, A., Lallemant-Le Coeur, S., Nzingoula, S., Mampaka, M., M’Pelé, P., Barin, F. & Essex, M. ( 1994; ). Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women. Lancet 343, 1001-1005.[CrossRef]
    [Google Scholar]
  25. Lombardi, S., Garzelli, C., Pistello, M., Massi, C., Matteucci, D., Baldinotti, F., Cammarota, G., Da Prato, L., Bandecchi, P., Tozzini, F. & Bendinelli, M. ( 1994; ). A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. Journal of Virology 68, 8374-8379.
    [Google Scholar]
  26. Montefiori, D. C., Lefkowitz, L. B.Jr, Keller, R. E., Holmberg, V., Sandstrom, E. & Phair, J. P. ( 1991; ). Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. AIDS 5, 513-517.[CrossRef]
    [Google Scholar]
  27. Montefiori, D. C., Pantaleo, G., Fink, L. M., Zhou, J. T., Zhou, J. Y., Bilska, M., Miralles, G. D. & Fauci, A. S. ( 1996; ). Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. Journal of Infectious Diseases 173, 60-67.[CrossRef]
    [Google Scholar]
  28. Moraillon, A., Barre-Sinoussi, F., Parodi, A., Moraillon, R. & Dauguet, C. ( 1992; ). In vitro properties and experimental pathogenic effect of three feline immunodeficiency viruses (FIV) isolated from cats with terminal disease. Veterinary Microbiology 31, 41-54.[CrossRef]
    [Google Scholar]
  29. O’Brien, W. A., Grovit-Ferbas, K., Namazi, A., Ovcak-Derzic, S., Wang, H.-J., Park, J., Yeramian, C., Mao, S.-H. & Zack, J. A. ( 1995; ). Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86, 1082-1089.
    [Google Scholar]
  30. Ortigao-de-Sampaio, M. B., Shattock, R. J., Hayes, P., Griffin, G. E., Linhares-de-Carvalho, M. I., Ponce de Leon, A., Lewis, D. J. & Castello-Branco, L. R. ( 1998; ). Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS 12, F145-F150.[CrossRef]
    [Google Scholar]
  31. Ostrowski, M. A., Krakauer, D. C., Li, Y., Justement, S. J., Learn, G., Ehler, L. A., Stanley, S. K., Nowak, M. & Fauci, A. S. ( 1998; ). Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. Journal of Virology 72, 7772-7784.
    [Google Scholar]
  32. Pancino, G., Leste-Lasserre, T., Burgard, M., Costagliola, D., Ivanoff, S., Blanche, S., Rouzioux, C. & Sonigo, P. ( 1998; ). Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer. Journal of Infectious Diseases 177, 1737-1741.[CrossRef]
    [Google Scholar]
  33. Pedersen, N. C., Ho, E. W., Brown, M. L. & Yamamoto, J. K. ( 1987; ). Isolation of T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235, 790-793.[CrossRef]
    [Google Scholar]
  34. Richardson, J., Moraillon, A., Baud, S., Cuisinier, A. M., Sonigo, P. & Pancino, G. ( 1997; ). Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. Journal of Virology 71, 9640-9649.
    [Google Scholar]
  35. Richardson, J., Moraillon, A., Crespeau, F., Baud, S., Sonigo, P. & Pancino, G. ( 1998; ). Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus. Journal of Virology 72, 2406-2415.
    [Google Scholar]
  36. Robinson, W. E.Jr, Montefiori, D. C. & Mitchell, W. M. ( 1987; ). A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. Biochemical and Biophysical Research Communications 149, 693-699.[CrossRef]
    [Google Scholar]
  37. Robinson, W. E.Jr, Kawamura, T., Lake, D., Masuho, Y., Mitchell, W. M. & Hersh, E. M. ( 1990; ). Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. Journal of Virology 64, 5301-5305.
    [Google Scholar]
  38. Robinson, W. E.Jr, Gorny, M. K., Xu, J. Y., Mitchell, W. M. & Zolla-Pazner, S. ( 1991; ). Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. Journal of Virology 65, 4169-4176.
    [Google Scholar]
  39. Schutten, M., Andeweg, A. C., Bosch, M. L. & Osterhaus, A. D. M. E. ( 1995; ). Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scandinavian Journal of Immunology 41, 18-22.[CrossRef]
    [Google Scholar]
  40. Schwartz, D. H. ( 1994; ). Potential pitfalls on the road to an effective HIV vaccine. Immunology Today 15, 54-57.[CrossRef]
    [Google Scholar]
  41. Siebelink, K. H. J., Tijhaar, E., Huisman, R. C., Huisman, W., de Ronde, A., Darby, I. H., Francis, M. J., Rimmelzwaan, G. F. & Osterhaus, A. D. M. E. ( 1995; ). Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. Journal of Virology 69, 3704-3711.
    [Google Scholar]
  42. Stanley, S., Ostrowski, M. A., Justement, J. S., Gantt, K., Hedayati, S., Mannix, M., Roche, K., Schwartzentruber, D. J., Fox, C. H. & Fauci, A. S. ( 1996; ). Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. New England Journal of Medicine 334, 1222-1230.[CrossRef]
    [Google Scholar]
  43. Staprans, S. I., Hamilton, B. L., Follansbee, S. E., Elbeik, T., Barbosa, P., Grant, R. M. & Feinberg, M. B. ( 1995; ). Activation of virus replication after vaccination of HIV-1-infected individuals. Journal of Experimental Medicine 182, 1727-1737.[CrossRef]
    [Google Scholar]
  44. Sullivan, N., Sun, Y., Li, J., Hofmann, W. & Sodroski, J. ( 1995; ). Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. Journal of Virology 69, 4413-4422.
    [Google Scholar]
  45. Sullivan, N., Sun, Y., Binley, J., Lee, J., Barbas, C. F.III, Parren, P. W. H. I., Burton, D. R. & Sodroski, J. ( 1998; ). Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. Journal of Virology 72, 6332-6338.
    [Google Scholar]
  46. Takeda, A., Tuazon, C. U. & Ennis, F. A. ( 1988; ). Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242, 580-583.[CrossRef]
    [Google Scholar]
  47. Talbott, R. L., Sparger, E. E., Lovelace, K. M., Fitch, W. M., Pedersen, N. C., Luciw, P. A. & Elder, J. H. ( 1989; ). Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 86, 5743-5747.[CrossRef]
    [Google Scholar]
  48. Toth, F. D., Szabo, B., Ujhelyi, E., Paloczi, K., Horvath, A., Fust, G., Kiss, J., Banhegyi, D. & Hollan, S. R. ( 1991; ). Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. AIDS 5, 263-268.
    [Google Scholar]
  49. Yamamoto, J. K., Ackley, C. D., Zochlinski, H., Louie, H., Pembroke, E., Torten, M., Hansen, H., Munn, R. & Okuda, T. ( 1991; ). Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology 32, 361-375.
    [Google Scholar]
  50. Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A. & Chen, I. S. Y. ( 1990; ). HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-10-2515
Loading
/content/journal/jgv/10.1099/0022-1317-83-10-2515
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error